Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Fluarix/Influsplit or Pandemrix in Previously Vaccinated Subjects
NCT01160237Phase 3Terminated
- Sponsor
- GSK
- Start
- Aug 2010
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Fluarix, Q-Pan H1N1 in influenza, sponsored by GSK. Started Aug 2010; status: terminated.
02
Drugs
FluarixQ-Pan H1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01160237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160237.